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Authorship guidelines have established criteria to guide author selection based on significance of contribution and helped
to define associated responsibilities and accountabilities for the published findings. However, low awareness, variable
interpretation, and inconsistent application of these guidelines can lead to confusion and a lack of transparency when
recognizing those who merit authorship. This article describes a research project led by the Medical Publishing Insights and
Practices (MPIP) Initiative to identify current challenges when determining authorship for industry-sponsored clinical trials
and develop an improved approach to facilitate decision-making when recognizing authors from related publications. A
total of 498 clinical investigators, journal editors, publication professionals and medical writers were surveyed to understand
better how they would adjudicate challenging, real-world authorship case scenarios, determine the perceived frequency of
each scenario and rate their confidence in the responses provided. Multiple rounds of discussions about these results with
journal editors, clinical investigators and industry representatives led to the development of key recommendations intended
to enhance transparency when determining authorship. These included forming a representative group to establish
authorship criteria early in a trial, having all trial contributors agree to these criteria and documenting trial contributions to
objectively determine who warrants an invitation to participate in the manuscript development process. The resulting
Five-step Authorship Framework is designed to create a more standardized approach when determining authorship for
clinical trial publications. Overall, these recommendations aim to facilitate more transparent authorship decisions and help
readers better assess the credibility of results and perspectives of the authors for medical research more broadly.
Please see related article: http://www.biomedcentral.com/1741-7015/12/214.
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Publication professionalsIntroduction
The designation of authorship is essential for published re-
search to be represented by those who provide significant
intellectual contribution to its development and execution.
More recently, authorship selection has evolved to confer
not only the credit for the research but also accountability
and responsibility for accuracy and integrity of the
work. Yet, making this determination can be especially
challenging due to the ambiguous nature of available* Correspondence: ana.marusic@mefst.hr
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unless otherwise stated.authorship guidelines and the increasing complexity of
clinical trial research [1]. The most common and fre-
quently referenced authorship guidelines in biomedicine
are issued by the International Committee of Medical
Journal Editors (ICMJE). The goal of the ICMJE criteria
is to enhance transparency in authorship disclosure and
ultimately to build trust and credibility with the medical
literature readership [2,3]. Another authorship model,
referred to as contributorship, lists each person’s contribu-
tions to the research and manuscript, even for those who
are not authors. One or more of these contributors will
fulfill the role as guarantors of the paper [4]. Despite im-
plementation of these and other approaches by journalsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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authorship contributions persist, which ultimately can
erode credibility in clinical trial research and related publi-
cations [5-10]. These authorship issues often arise in situa-
tions where established definitions and guidelines are
ambiguous, resulting in variations in interpretation and
application that can contribute to a lack of transparency
[11]. While ICMJE authorship guidance is intentionally
broad to accommodate the diversity of scientific research,
a more structured authorship framework is needed to im-
prove consistency and clarity in authorship decision-
making for clinical trials given the complexity in design
and ongoing evolution [12,13].
Improving disclosure of authorship contributions and
writing assistance was identified as one of ten recommen-
dations to close the credibility gap in reporting industry-
sponsored research by the Medical Publishing Insights
and Practices (MPIP) Initiative [14], a collaboration among
pharmaceutical companies with representation from the
International Society for Medical Publication Professionals
(ISMPP) aimed at elevating trust, transparency and in-
tegrity in publishing industry-sponsored studies [15].
This article describes a research collaboration between
the MPIP Initiative and academic researchers to iden-
tify and address challenging authorship case scenarios for
industry-sponsored clinical trials. Discussions about these
results with journal editors, clinical investigators, aca-
demic collaborators and industry representatives allowed
the MPIP Initiative to develop a Five-Step Authorship
Framework that facilitates a more prospective, transparent
and consistent process when determining authorship for
industry-sponsored publications.
Methods
Creation of authorship scenarios
In early 2012, members of the MPIP Initiative’s Steering
Committee collaborated with multiple respondent groups
involved in publication of industry-sponsored clinical trials
to identify authorship challenges arising from current
guidelines. Following in-depth discussions with seven pub-
lication professionals (individuals employed or contracted
by industry to organize and disseminate scientific and clin-
ical data through peer reviewed publications), three jour-
nal editors and three clinical investigators, the MPIP
Initiative Steering Committee and its academic collabora-
tors converted these challenging situations into authorship
case scenarios for further testing. An additional flow dia-
gram provides a detailed overview of the authorship re-
search project [see Additional file 1].
Survey development, validation, and analysis
An online survey utilizing these authorship case scenarios
was created to collect qualitative data regarding the ration-
ale for adjudication of authorship decisions in individualcases (that is, granting of authorship, acknowledgement,
no recognition, other). The survey also asked for confi-
dence level in authorship decisions and perceived fre-
quency of the situation described in the case. Respondents
were asked to answer based on their professional expe-
rience, as cases did not mention any specific guidelines. At
the end of the survey, respondents were also asked about
their awareness of and reliance on specific authorship
guidelines, as well as the time point during the clinical
trial when they would agree on authorship criteria. The
full survey [see Additional file 2] was piloted for content
and clarity among a convenience sample of five pro-
fessionals with experience in publishing or editing clinical
trials results. The final survey was created after revising
the original version based on comments generated during
pilot testing.
The survey was sent via an email link (to avoid duplicate
answers) to four respondent groups involved in the publi-
cation of clinical trial results: clinical investigators involved
in industry-sponsored clinical trials (as of September
2012), editors of general or specialty journals who publish
results from industry-sponsored clinical trials (contacted
directly by the MPIP Initiative, collaborating publishers, or
collaborating editors), publication professionals (as defined
above) and medical writers employed or contracted by
trial sponsors who collaborate with authors in drafting, re-
vising and editing medical information for peer-reviewed
journals and congresses. The last two groups were con-
tacted through ISMPP, the American Medical Writers
Association (AMWA), the European Medical Writers
Association (EMWA) and the MPIP Initiative Steering
Committee. Cases were presented randomly to minimize
respondent fatigue. From a total of 498 responses, a sam-
ple of at least 96 participants per group enabled estimates
with a 10% margin of error for the largest respondent
group surveyed (clinical investigators). The online survey
remained open until all groups surpassed this sample size
by at least 10%.
Adjudications of cases, confidence in answers, and
authorship practices of respondents were summarized
as frequencies. The answers measuring respondents’
confidence and perceived frequency of scenarios were
captured on 6 point scales and categorized into three
groups: high confidence/frequency (score 1–2), moder-
ate confidence/frequency (score 3–4) and low confi-
dence/frequency (score 5–6). Open-ended explanations
for adjudications were analyzed as qualitative data. An-
swers were summarized and analyzed using a general
inductive approach [16]. Participants’ answers related
to each case were analyzed and then common themes
were identified through initial coding [17]. Overlapping
themes were then grouped and the final set of themes
developed. Data were coded and analyzed using NVivo
10 (QSR International Pty Ltd., Warrington, UK).
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Quantitative survey results were discussed at two separate
MPIP-hosted roundtable meetings: 10 U.S.-based editors
and 15 MPIP members (New York, USA, December
2012), and five European-based editors, one journal repre-
sentative, and seven MPIP members (Alderley Park, UK,
April 2013). During these roundtables, a facilitator pre-
sented quantitative results from the survey-based study.
Through an iterative process of discussion and consensus
building, key themes were identified. Findings were further
refined through analysis of qualitative survey answers and
in-depth discussions with six clinical investigators who




Survey respondents (n = 498) included representation from
all four target respondent groups: 145 clinical investigators
(29% of respondents), 108 journal editors (22%), 132 publi-
cation professionals (26%) and 113 medical writers (23%)
(Table 1). The survey reached an international audience,
from North America (44%) and Europe (39%) to Asia
(13%). A majority of respondents had >5 years of industry-
sponsored clinical trial experience (82%) and clinical inves-
tigators surveyed had published ≥3 papers from that
research (63%). Given the various methods used to contactTable 1 Survey respondent demographics
Characteristic Frequency Percent
Respondent group:
Clinical investigator 145 29.1
Journal editor 108 21.7
Publication professional 132 26.5
Medical writer 113 22.7
Total 498 100.0
Years associated with industry-sponsored clinical trial:
3 to 5 years 89 17.9
6 to 10 years 116 23.3
11 to 20 years 176 35.3
20+ years 117 23.5
Total 498 100.0
Number of industry-sponsored clinical trial publications as an
author in the past 10 yearsa
0 to 2 papers 54 37.2
3 to 5 papers 38 26.2
6 to 10 papers 21 14.5
11 to 20 papers 17 11.7
20+ papers 15 10.4
Total 145 100.0
aNote: Clinical investigators only.potential respondents and collect survey data, it was not
possible to calculate a response rate or determine any dif-
ferences between respondents and those who did not take
the survey.
Authorship guidelines
Following completion of the case scenario section, respon-
dents were asked about their familiarity and reliance on
guidelines applicable to industry-sponsored clinical trial
manuscripts. Respondents were most familiar with ICMJE
authorship guidelines (49% to 97%), followed by the Good
Publication Practice (GPP2) guidelines [18] (35% to 87%)
(Figure 1). Clinical investigators were significantly less fa-
miliar with these two guidelines (49% and 41%, respect-
ively) and more often than other groups reported they
were not aware of any guidelines (28%). Publication pro-
fessionals had the highest awareness of ICMJE (97%) and
GPP2 (87%) guidelines, mirroring results from previous
surveys of this professional group [19]. When asked about
reliance on other authorship guidelines in addition to spe-
cific journal guidelines, all respondents selected ICMJE as
their top choice, although this was less the case among
clinical investigators (28%) than other respondent groups
(51% to 70%). Clinical investigators reported using no
guidelines (25%) more frequently than other groups (2%
to 10%) when deciding questions of authorship.
Authorship case scenario responses
Full descriptions of the seven hypothetical authorship
case scenarios for industry-sponsored studies and an-
swers by respondent group are presented in Figure 2
and Additional file 3: Table S1. We describe in more de-
tail the cases with greater disagreement among respond-
ent groups and relevance for industry-sponsored clinical
trials.
Case 1 tests whether patient recruitment and trial site
management were perceived to be significant enough
contributions to merit an authorship invitation. Most of
the respondents (49% to 68%) agreed that these contri-
butions warranted an invitation to authorship. The ra-
tionale for this decision is illustrated by the response
from a clinical investigator: ‘Recruiting patients is one of
the most important tasks in a clinical trial, and the qual-
ity of the study depends on compliance with the inclu-
sion and exclusion criteria. Therefore, this is probably
one of the most important persons for the study, and
should therefore take responsibility/be acknowledged as
an author.’ This case was estimated by respondents to
occur most frequently, and >73% of respondents in each
group were confident in their answer. ICMJE criteria for
authorship available at the time of the survey [20] were
unclear as to whether patient recruitment was consid-
ered to be a substantial contribution as part of data
acquisition.
Figure 1 Respondents’ familiarity (A) with and reliance (B) on authorship guidelines. More than one guideline could be chosen for
familiarity. CSE, Council of Science Editors; EMWA, European Medical Writers Association; GPP2, Good publication practice for communicating
company sponsored medical research; ICMJE, International Committee of Medical Journal Editors; ISMPP, International Society of Medical
Publication Professionals.
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who is believed to have made a substantial contribution
but did not contribute to trial design or drafting of the
manuscript merits an invitation to authorship; and 2)
whether timing of authorship criteria fulfillment impacts
the decision. More publication professionals supported
consideration for authorship (72%) compared to clinical
investigators (54%). Qualitative responses highlighted a
lack of consensus between respondent groups. One editor
commented that ‘Authorship on a manuscript needed to
be decided before the writing of a first draft’, in contrast to
a clinical investigator who wrote ‘Authorship should reflect
a significant contribution to the substance of the study - it
was an error not to include this person from the start.’
While respondents had generally high confidence in their
answers (>72% for all groups), they reported moderate fre-
quency for this case. ICMJE criteria in place at the time of
the survey [20] provided guidance on authorship criteriabut did not address the issue of timing for the fulfillment
of the criteria.
Case 3 asks if a contribution from a medical writer
could qualify the person as an author. In this case, a
medical writer is hired to help draft the manuscript from
a trial report and supports authors in manuscript devel-
opment under the guidance of the authors to final ac-
ceptance. Nearly one quarter of journal editors (23%)
and clinical investigators (25%) supported authorship in
this case. Respondents were aware this choice was not
concordant with guidelines, exemplified by a clinical in-
vestigator: ‘I believe medical writers should be listed as
authors in those instances where they have contributed
from the first draft through to submission. (I recognize
that this would require revision of ICMJE guidelines).’
This case was estimated by respondents to be the second
most frequent, and >76% of respondents in each group
were confident in their answer. ICMJE guidelines at the
Figure 2 Case scenario adjudication responses by respondent group. Abbreviations: CI, Clinical investigator; JE, Journal editor; MW, Medical writer;
PP, Publication professional. Confidence in adjudication and perceived frequency of scenarios were captured on 6 point scales and categorized into
three categories: high confidence/frequency (score 1-2), moderate confidence/frequency (score 3-4) and low confidence/frequency (score 5-6). "Don't
know" responses (<10% for any group) are not included.
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nical editing, language editing, and proofreading did not
qualify as a substantial contribution.
Finally, Case 7 tests whether providing those who make
a significant contribution the opportunity to serve as an
author takes precedence over protection of proprietary in-
formation. In this scenario, respondents were asked if a
clinician who leaves a trial sponsor company for a com-
petitor after making a substantial contribution but prior to
drafting the manuscript should be invited to contribute as
an author. A majority of clinical investigators (61%) and
journal editors (55%) were in favor of inviting the clinician
to serve as an author versus publication professionals
(26%) and medical writers (36%). As with other cases, re-
spondents were more often concerned about what was fair
and not what was prescribed, as noted by a publication
professional: ‘Honestly speaking, I think the clinician
should be recognized as an author, but he does not meet
authorship criteria.’ More than 72% of respondents in each
group were confident in their answer. This case was esti-
mated to occur relatively infrequently.
When considering answers from the cases as a whole,
three overarching insights emerged. First, responses per-
taining to granting authorship, acknowledgement, no rec-
ognition or other, varied not only across but within the
four respondent groups for each case. This variability sug-
gests limited agreement within peer groups as to how to
determine authorship on challenging cases, as well as dif-
ferences in opinion between the respondent groups. Sec-
ond, a majority of respondents in all groups were confident
in their answers regardless of the case subject, answer
choice or perceived frequency. Finally, analysis of 2,841 out
of 3,486 possible open-ended answers (81% response rate)
highlighted key justifications underlying authorship deci-
sions in the survey (Table 2). These themes included the
importance or significance of the contribution for each sce-
nario, alignment or misalignment with formal authorship
guideline criteria, importance of transparency and/or re-
sponsibility and need for prior agreement on authorship
criteria [see Additional file 4 for example answers]. The
group of respondents who would grant authorship in caseTable 2 Themes used in adjudication answers when
invitation for authorship was chosen versus all other
answers
Number of references coded within
the theme (% of all coded references
within the adjudication choice/choices)
Theme Grant authorship Acknowledgement/
No authorship/Other
Importance of contribution 608 (57%) 381 (30%)
Formal criteria 277 (26%) 478 (38%)
Transparency/Responsibility 149 (14%) 319 (26%)
Agreement in advance 30 (3%) 69 (6%)scenarios more often used the ‘importance of contribu-
tions’ in explaining their adjudication (57%) versus
those who would grant acknowledgment or not offer
authorship. The latter respondents most often cited
the following rationales: ‘importance of contribution’
(30%), application of ‘formal criteria’ (38%) and ‘trans-
parency/responsibility’ (26%).
As clinical investigators with two or fewer published
articles from clinical trials constitute approximately a
third of the respondent population (Table 1), we com-
pared case adjudications from this group with that from
other respondents. This sensitivity analysis revealed a
difference only for Case 1, where relatively inexperienced
clinical investigators would be less likely to invite a clin-
ical investigator who enrolled the most patients to help
draft/revise the manuscript. There were no differences
in confidence or perceived frequency of the case scenar-
ios, suggesting that publication experience had minimal
influence on the answers provided.
Consultations with editors
The quantitative survey results from the case scenarios
were shared with fifteen U.S. and five European-based
journal editors and one journal representative across two
separate discussion-based roundtables to gain further in-
sights and begin developing recommendations. Feedback
highlighted the following areas to help improve author-
ship disclosure:
 Authorship criteria should be determined as early as
possible in the course of a clinical trial;
 Authorship criteria can vary between clinical trials,
assuming current guidelines are followed;
 Authorship criteria should be agreed to by all trial
contributors via authorship agreements;
 Trial contributions should be documented and
summarized prior to publication; and,
 The entire author list should agree to any
authorship changes during the publication process.
Quantitative survey results and these preliminary themes
were subsequently discussed with six clinical investigators
from our survey sample via in-depth teleconference inter-
views to help further refine initial recommendations.
Five-step authorship framework
Using input from quantitative survey results, analysis
of qualitative open-ended answers, and discussions
with journal editors, clinical investigators and industry
representatives, key themes were identified that led to
the development of the following ‘Five-Step Authorship
Framework to Improve Transparency in Disclosing Con-
tributors to Industry-sponsored Clinical Trial Publications
(Table 3).
Table 3 Five-Step Authorship Framework to Improve Transparency in Disclosing Contributors to Industry-sponsored
Clinical Trial Publications
Step Tasks
1 Establish an authorship working group of core trial contributors as close as possible to trial commencement but prior to enrollment of first
patient. For smaller trials where an authorship working group is not feasible, this committee may be a sub-committee of a larger Trial Steering
Committee where one exists.
2 Determine, in the context of the ICMJE authorship criteria and the specific trial, which authorship contributions will qualify as ‘substantial’ and
include these details in written publication agreements for all trial contributors.
3 Implement a process to track and document in a concise format progress toward substantial contributions based on agreed-upon
qualifications.
4 Assess documented trial contributions for the specific study and invite those making a ‘substantial contribution’ to participate as author(s).
5 Ensure invited authors meet remaining ICMJE authorship criteria during content development and publication submission.
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trial
This working group should include core trial contributors
with broad representation from multiple disciplines, in-
cluding the trial Steering Committee, clinical investigators
with relevant expertise, study co-sponsors and external
experts. Where possible, these working group members
should remain unchanged throughout the study to help
ensure continuity. Members of the working group need
not be authors nor should they be guaranteed authorship
without meeting authorship criteria for the trial.
Step 2 – Determine substantial contribution criteria
The primary task for the authorship working group is to
determine prospectively which contributions will qualify
as ‘substantial’ in the context of trial activities. These cri-
teria should align with external guidelines (for example,
ICMJE, GPP2 and journals being considered for submis-
sion) and policies of the sponsor, and they should be fi-
nalized prior to first patient enrollment. Standardized
language for those criteria should be included in written
publication agreements and agreed to by all trial contrib-
utors, including those in the authorship working group.
When determining these authorship criteria, trial activ-
ities meriting an invitation for authorship should be eva-
luated by their ability to impact broader trial outcomes
compared to those serving a more narrow function. It is
important to note that definitions for substantial contribu-
tions can differ between trials, provided external guidelines
such as ICMJE are followed, since trial activities vary greatly
across therapeutic areas, stages of development, sponsors
and other dimensions. When considering large, multi-
national trials, it is especially important to clearly determine
substantial contribution criteria as early as possible in the
trial, given the large number of contributors involved.
Step 3 – Document trial contributions
In addition to setting the criteria for substantial contri-
bution, the authorship working group should create
a process for tracking and documenting all relevant
trial contributions that meet the pre-defined criteria assubstantial. This process should be made transparent in
the written publication agreement, and trial contributors
should be notified of the requirement to provide this in-
formation as part of ongoing trial responsibilities. To
avoid creating new tasks and expense, tracking should
be included among normal trial activities where possible.
Step 4 – Determine those making a substantial contribution
Once trial activities for a given manuscript are completed,
the authorship working group should reconvene to apply
the criteria to the documented contributions. All trial con-
tributors, regardless of function, responsibility or relation-
ship to trial sponsor(s), meeting the authorship criteria for
substantial contribution determined in Step 2 should then
be invited to draft/revise the manuscript. However, an in-
vitation for authorship may be declined by a contributor.
As part of our discussions with journal editors and clinical
investigators, it was noted that while up-front participa-
tion is preferred, later contributions sometimes rise to the
level of a substantial contribution. The authorship working
group should have the responsibility to determine which
potential authors made a substantial contribution based
on the contribution data and adjudicate disagreements
that arise from its decisions. Contributions which do not
meet the standard for ‘substantial’ should be agreed to by
all authors and noted in the acknowledgements.
Step 5 – Ensure authors meet remaining authorship criteria
Those who accept an invitation to draft/revise the
manuscript will serve as the initial author list. The final
responsibility of the authorship working group is to en-
sure timely dissemination of findings that are consistent
with the pre-specified aims of the clinical trial. Those in
the author list should agree on their role prior to drafting
the manuscript and all contributions should be fully docu-
mented. It is important that members of the author list
fulfill the remaining authorship criteria beyond substantial
contribution outlined in the written publication agree-
ment. Changes to the author list can occur, either adding
those who make a later substantial contribution or remov-
ing those who do not fulfill all authorship requirements.
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and the accompanying rationale should be documented
and agreed to by the entire author list. At submission, the
authors should consider providing a summary of the au-
thor list and their specific contributions to indicate how
authorship was determined.
Discussion
Given the growing demand for increased transparency in
publications for clinical trials [21-24], the MPIP Initiative
sought to identify authorship ambiguities encountered in
industry-sponsored trials not well addressed by current
guidelines and to develop an approach by which author-
ship decisions can be more clearly and easily determined.
Investigation of the rationale used by the respondent
groups in adjudicating challenging case scenarios identi-
fied a number of key gaps between authorship guidelines
and how these scenarios are addressed. Most important
among these, survey results highlighted the variability in
responses both across and within peer groups despite
some groups having high familiarity with and reliance on
current authorship guidelines. Some cases also tested a
number of areas where authorship criteria do not explicitly
provide guidance, such as whether patient recruitment is
considered a substantial contribution or the impact of tim-
ing on authorship criteria fulfillment [20], which further
contributed to response variability. These findings suggest
the lack of clear authorship guidance on some scenarios
frequently encountered in real life, and indicate that re-
spondents acting on judgment contrary to guidance can
contribute to lack of transparency. Second, despite this het-
erogeneity, respondents were uniformly confident in their
own rationale for these authorship decisions. Since the sur-
vey did not specify or refer to any guidelines during the
case scenario section, respondents likely believed their ex-
perience and judgment are a correct approach to resolving
these scenarios. Finally, clinical investigators, who make up
a significant percentage of authors on manuscripts from
clinical trials, appear to be concerned with the importance
or significance of the contribution rather than following ex-
ternal guidelines to determine authorship. This perspective
is exemplified by clinical investigators ranking lowest among
the groups surveyed for awareness of authorship criteria.
Through discussions with journal editors, clinical in-
vestigators and industry representatives on the gaps in
authorship decision-making that emerged from the survey,
we identified key themes for improvement. These themes
included defining the criteria for substantial contributions
early in the trial, ensuring all trial contributors agree to
these criteria and documenting contributions to ensure
these criteria are met. Expanding on these key insights,
the Five-step Authorship Framework was developed to
provide a clear and flexible process to facilitate more
transparent and consistent authorship decision-making.The success of the Five-Step Authorship Framework re-
lies significantly on convening a working group early in
the trial process to discuss which trial activities should be
considered a substantial contribution in the context of
current authorship guidelines. Given the wide diversity of
trials undertaken and likely future changes in authorship
guidelines, defining a comprehensive set of potential activ-
ities that meet the definition of ‘substantial’ for authorship
is neither practical nor durable. Instead, utilizing the ex-
perience and judgment of a diverse group of core trial
contributors in an open discussion format provides a
transparent process for determining fair and comprehen-
sive authorship criteria for a given trial. In addition, these
authorship criteria should align with external guidelines,
such as ICMJE and GPP2, to avoid potential bias in
selection of criteria that exclude legitimate authorship.
Documenting these definitions in authorship agreements
ensures that all trial contributors are informed in advance
and provides a basis for conflict resolution should a
dispute arise. The flexibility of this framework permits
authorship criteria specific to each trial, as some trial
groups may define significant patient recruitment to be a
substantial contribution while others may not (see Case
1). This adaptable format will help facilitate the continued
movement away from patient recruitment as sole criteria
for substantial contribution and place greater emphasis on
intellectual contributions, thus better aligning with the
evolving concept of authorship.
The authorship working group should also be respon-
sible for determining who has fulfilled the criteria of
substantial contribution to help draft the manuscript,
ensuring the results are consistent with the aims of
the trial. The initial author list should be determined
through matching the documented contributions of po-
tential pre-specified authors to the authorship criteria.
In this way, the authorship working group would have a
data-driven approach to determine which potential au-
thors fulfill criteria 1 of the ICMJE authorship recommen-
dations (see Cases 3, 5 to 7). In addition, the pre-specified
author criteria provide an objective basis for evaluating
whether to add or remove an author as contributions come
to light during manuscript development (see Cases 2 and
4). Given the importance of its responsibilities, the author-
ship working group should be a stand-alone group and not
subsumed into the trial Steering Committee. As outlined,
the authorship working group will not require substantial
additional burden and, hence, convening such a group
should be feasible.
Our survey results identified divergent opinions both
within and across respondent groups for how to adjudi-
cate the cases, with varying awareness and reliance
on authorship guidelines. Previous research has shown
that authorship issues can be seen as either matters of
defined rules or obligation [25]. Decisions about issues
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for obligation, higher order rules define the right and
wrong courses for action, and decisions are not contin-
gent on specific social rules [26]. Our research confirms
that authorship decisions bring forth issues both based
on rules (‘formal criteria’) and obligation (‘importance of
contributions’), and participants try to compromise be-
tween these perspectives. Our finding that trial publication
experience has little influence on the scenario adjudication
suggests these opinions are not generated by clinical trial
experience but are rather a characteristic inherent to the
professionals taking part in clinical trials. Therefore, form-
ing a diverse group early in the trial can facilitate this
process by bringing together those who are more aware of
guidelines and setting mutually agreed upon authorship
criteria from both domains through broad discussion.
These findings also independently align with the recent
change in ICMJE authorship requirements, which added
accountability for all aspects of work described in the
manuscript as the fourth criterion [2].
Our study has limitations related to its methodological
approach, which was focused on collecting qualitative input
from professional groups involved in industry-sponsored
clinical trial publications rather than quantitative data,
which can be difficult to collect via online surveys [27,28].
The survey contained the possibility for self-selection bias,
with respondents potentially having a special interest in
authorship and, therefore, not being representative. How-
ever, the survey was not meant to collect representative
input across all relevant characteristics from the four re-
spondent groups but to learn about possible approaches to
solving real-life authorship challenges in clinical research to
inform potential solutions to these problems. In addition,
the Five-step Authorship Framework will not resolve all
authorship questions, especially as clinical trials continue to
evolve in complexity. We see the Framework as a living
guideline that will change together with clinical research.
The companies included in this publication will support
implementation of this tool in their clinical trials to sup-
plement best practice and would encourage other industry
members to do so as well to ensure this framework is
broadly embedded for maximum impact. Given the con-
tribution from other stakeholders, such as journal editors,
the authors will be reaching out to them and other organi-
zations to ask for their help to foster awareness and up-
take for the Five-step Framework.
Conclusions
This research outlines an approach for manuscripts from
industry-sponsored clinical trials that emphasizes early de-
termination of substantial contribution by a diverse group of
core participants, clear communication of authorship cri-
teria to all participants and documentation of contributions
that leads to less opaque authorship decisions. This Five-Step Authorship Framework has the potential to facilitate
decision-making with improved transparency and
consistency when recognizing authors for all clinical trial
publications, not just those from industry-sponsored efforts.
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